newsfilter
← Latest News
Business Wire·

Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

PACIFIC-9 Phase 3 trial led by AstraZeneca evaluates durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA)